Portola Pharmac (PTLA) Edges Out Q2 Expectations

Portola Pharmac (NASDAQ: PTLA) reported Q2 EPS of ($0.76), $0.03 better than the analyst estimate of ($0.79). Revenue for the quarter came in at $2.4 million versus the consensus estimate of $2.44 million.

For earnings history and earnings-related data on Portola Pharmac (PTLA) click here.

You May Also Be Interested In

• North American Construction (NOA) Tops Q2 EPS by 9c; Offers Guidance
• Southland Holdings (SLND) Misses Q2 EPS by 122c
• Lumexa Imaging Holdings, Inc. (LMRI) Reports In-Line Q2 EPS; Offers Guidance